Last updated on May 2019

Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Endstage Renal Disease
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Age
  2. 45 years or
  3. 18 with a history of diabetes
  4. On dialysis 90 days
  5. On either
  6. Hemodialysis prescribed at least 2 treatments per week or
  7. Peritoneal dialysis prescribed with at least 1 exchange daily
  8. Provides informed consent

Exclusion Criteria:

  1. Hyperkalemia
  2. Serum potassium >5.8 mmol/L in the 6 weeks prior to enrollment or
  3. Serum potassium >6.0 mmol/L during active run-in
  4. Currently taking and unable to withdraw a mineralocorticoid receptor antagonist (i.e. spironolactone or eplerenone).
  5. Known sensitivity or allergy to spironolactone
  6. Current or planned pregnancy or breastfeeding
  7. Scheduled living related donor renal transplant
  8. Life expectancy < 6 months in the opinion of a treating nephrologist.
  9. Enrolled in another interventional trial testing a mineralocorticoid receptor antagonist or drug that has a known or likely interaction with spironolactone.
  10. Treating physician believes either spironolactone is either absolutely indicated or absolutely contra-indicated

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.